Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92518 | 0.92 | L3MBTL1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7326919 | 0.84 | MEN1 (0.52) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL8522162 | 0.83 | SMN1; SMN2 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7502314 | 0.83 | MAPK1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL25551746 | 0.82 | TMEM97 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1570844 | 0.80 | MEN1 (0.57) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL5109854 | 0.80 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1000788 | 0.80 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7424105 | 0.80 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2440342 | 0.80 | TMEM97 (0.57) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4472980-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| CN-118660880-A | Quinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023150284-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
| EP-2220073-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063244-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | KRAS, NRAS, HRAS | MEN1 296/4885KMT2A 1761/4885NPSR1 4164/4885 |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | MEN1 3563/4885KMT2A 3180/4885NPSR1 4377/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 948/4885KMT2A 1207/4885NPSR1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.